Sartorius has acquired a majority stake in CellGenix for $118 million, expanding its cell and gene therapy portfolio. Sartorius has acquired 51% of reagent manufacturing firm CellGenix for around $118 million in cash with plans to buy the remaining shares in 2023 and 2026. The firm anticipates that the acquisition will expand its cell and gene therapy portfolio through the addition of cytokines and media. “CellGenix has an excellent reputation on the market and brings in high technological expertise and…